Pub Date : 2025-01-07DOI: 10.1007/s11892-024-01572-0
Pablo Corral, Natalia Nardelli, Alicia Elbert, Florencia Aranguren, Laura Schreier
Purpose of review: This article explores the cardiovascular effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM), with a particular focus on their impact on lipid profiles. As evidence grows of the cardiovascular benefits of SGLT2i beyond glucose control, it is essential to better understand their effects on lipoproteins and their impact on cardiovascular disease.
Recent findings: SGLT2i have shown significant cardiovascular benefits in patients with type 2 diabetes mellitus, beyond their role in lowering blood glucose. Studies indicate that SGLT2i reduce major adverse cardiovascular events by impacting factors such as blood pressure, body weight, and arterial stiffness. However, their effects on lipid profile remain complex and somewhat inconsistent. Some research points to modest increases in LDL cholesterol, while others report shifts toward less atherogenic lipid profile, including reductions in triglycerides and small, dense LDL particles, and increases in HDL-C. SGLT2i represent a significant advancement in managing diabetes and associated cardiovascular risks, with benefits such as triglyceride reduction and HDL-C increase. While their impact on LDL-C remains controversial and varies across studies, the reduction of small, dense LDL particles may mitigate negative effects. This article highlights the need for future research to better understand the specific mechanisms behind lipid modulation.
{"title":"Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes.","authors":"Pablo Corral, Natalia Nardelli, Alicia Elbert, Florencia Aranguren, Laura Schreier","doi":"10.1007/s11892-024-01572-0","DOIUrl":"https://doi.org/10.1007/s11892-024-01572-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>This article explores the cardiovascular effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM), with a particular focus on their impact on lipid profiles. As evidence grows of the cardiovascular benefits of SGLT2i beyond glucose control, it is essential to better understand their effects on lipoproteins and their impact on cardiovascular disease.</p><p><strong>Recent findings: </strong>SGLT2i have shown significant cardiovascular benefits in patients with type 2 diabetes mellitus, beyond their role in lowering blood glucose. Studies indicate that SGLT2i reduce major adverse cardiovascular events by impacting factors such as blood pressure, body weight, and arterial stiffness. However, their effects on lipid profile remain complex and somewhat inconsistent. Some research points to modest increases in LDL cholesterol, while others report shifts toward less atherogenic lipid profile, including reductions in triglycerides and small, dense LDL particles, and increases in HDL-C. SGLT2i represent a significant advancement in managing diabetes and associated cardiovascular risks, with benefits such as triglyceride reduction and HDL-C increase. While their impact on LDL-C remains controversial and varies across studies, the reduction of small, dense LDL particles may mitigate negative effects. This article highlights the need for future research to better understand the specific mechanisms behind lipid modulation.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"16"},"PeriodicalIF":5.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-04DOI: 10.1007/s11892-024-01571-1
Jessica Odom, Rebecca Goldstein
Purpose of review: Hypoglycemia has been shown to increase mortality and length of hospital stay and is now reportable to the Centers for Medicare and Medicaid Services as a quality measure. The purpose of this article is to review clinical decision support (CDS) tools designed to reduce inpatient hypoglycemic events.
Recent findings: CDS tools such as order set development, medication alerts, and data visibility have all been shown to be valuable tools in improving glycemic performance. This is especially true for hyperglycemic events with mixed results in hypoglycemia prevention. CDS solutions may be targeted directly to healthcare professionals or to specialty diabetes management teams to reduce hypoglycemia. Not all organizations have the financial resources to develop a diabetes management team so non-interruptive alerts may serve as an important tool to alert health care professionals of individuals with additional risk factors for the development of hypoglycemia. CDS can provide a mechanism to reduce the risk of hypoglycemia in hospitalized individuals. Although new research is promising, more studies are needed to determine future directions including the impact and feasibility of continuous glucose monitoring and predictive models to improve overall glycemic performance.
{"title":"Inpatient Hypoglycemic Rate Reduction Through the Implementation of Prescriber Targeted Decision Support Tools.","authors":"Jessica Odom, Rebecca Goldstein","doi":"10.1007/s11892-024-01571-1","DOIUrl":"10.1007/s11892-024-01571-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypoglycemia has been shown to increase mortality and length of hospital stay and is now reportable to the Centers for Medicare and Medicaid Services as a quality measure. The purpose of this article is to review clinical decision support (CDS) tools designed to reduce inpatient hypoglycemic events.</p><p><strong>Recent findings: </strong>CDS tools such as order set development, medication alerts, and data visibility have all been shown to be valuable tools in improving glycemic performance. This is especially true for hyperglycemic events with mixed results in hypoglycemia prevention. CDS solutions may be targeted directly to healthcare professionals or to specialty diabetes management teams to reduce hypoglycemia. Not all organizations have the financial resources to develop a diabetes management team so non-interruptive alerts may serve as an important tool to alert health care professionals of individuals with additional risk factors for the development of hypoglycemia. CDS can provide a mechanism to reduce the risk of hypoglycemia in hospitalized individuals. Although new research is promising, more studies are needed to determine future directions including the impact and feasibility of continuous glucose monitoring and predictive models to improve overall glycemic performance.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"15"},"PeriodicalIF":5.2,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-30DOI: 10.1007/s11892-024-01565-z
Allyson S Hughes, Karissa Mirus, Nazanin M Heydarian, Michelle L Litchman
Purpose of review: Describe the connection between Deaf/hard of hearing (DHH) and diabetes, explain the bidirectional relationship of blind/low vision (BLV) and diabetes, characterize challenges DHH and BLV populations face when seeking healthcare regarding their diabetes management. Highlight the inaccessibility of diabetes technology in these populations. Provide best practices when communicating with DHH and BLV people in the clinical setting.
Recent findings: Diabetes disparities exist in DHH and BLV populations due to systemic barriers to health equity related to access and communication. Structural barriers, risk factors, social determinants of health, and the U.S. healthcare system do not support the DHH and BLV communities. Importantly, healthcare professionals do not receive adequate training on communication and treatment of DHH and BLV populations. Together, social determinants of health, such as healthcare access and quality, education access and quality, and lack of adequate clinician training allow ableism to persist and drive health disparities in these communities. Health disparities faced by DHH and BLV populations are driven by barriers to diabetes standards of care. These inequities must be rectified to improve and maintain high quality care.
{"title":"Diabetes Care Disparities in Deaf/Hard of Hearing and Blind/Low Vision Populations.","authors":"Allyson S Hughes, Karissa Mirus, Nazanin M Heydarian, Michelle L Litchman","doi":"10.1007/s11892-024-01565-z","DOIUrl":"10.1007/s11892-024-01565-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Describe the connection between Deaf/hard of hearing (DHH) and diabetes, explain the bidirectional relationship of blind/low vision (BLV) and diabetes, characterize challenges DHH and BLV populations face when seeking healthcare regarding their diabetes management. Highlight the inaccessibility of diabetes technology in these populations. Provide best practices when communicating with DHH and BLV people in the clinical setting.</p><p><strong>Recent findings: </strong>Diabetes disparities exist in DHH and BLV populations due to systemic barriers to health equity related to access and communication. Structural barriers, risk factors, social determinants of health, and the U.S. healthcare system do not support the DHH and BLV communities. Importantly, healthcare professionals do not receive adequate training on communication and treatment of DHH and BLV populations. Together, social determinants of health, such as healthcare access and quality, education access and quality, and lack of adequate clinician training allow ableism to persist and drive health disparities in these communities. Health disparities faced by DHH and BLV populations are driven by barriers to diabetes standards of care. These inequities must be rectified to improve and maintain high quality care.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"14"},"PeriodicalIF":5.2,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-18DOI: 10.1007/s11892-024-01569-9
Giovane G Tortelote
Purpose of review: This review explores the mechanisms through which gestational diabetes mellitus GDM impacts fetal kidney development, focusing on epigenetic alterations as mediators of these effects. We examine the influence of GDM on nephrogenesis and kidney maturation, exploring how hyperglycemia-induced intrauterine stress can reduce nephron endowment and compromise renal function via dysregulation of normal epigenetic mechanisms.
Recent findings: In addition to metabolic impacts, emerging evidence suggests that GDM exerts its influence through epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA expression, which disrupt gene expression patterns critical for kidney development. Recently, specific epigenetic modifications observed in offspring exposed to GDM were implicated in aberrant activation or repression of genes essential for kidney development. Key pathways influenced by these epigenetic changes, such as oxidative stress response, inflammatory regulation, and metabolic pathways, are discussed to illustrate the broad molecular impact of GDM on renal development. Finally, we consider potential intervention strategies that could mitigate the adverse effects of GDM on kidney development. These include optimizing maternal glycemic control, dietary modifications, dietary supplementation, and pharmacological agents targeting epigenetic pathways. Through a comprehensive synthesis of current research, this review underscores the importance of early preventive strategies to reduce the burden of kidney disease in individuals exposed to GDM and highlights key epigenetic mechanisms altered during GDM that impact kidney development.
{"title":"The Impact of Gestational Diabetes on Kidney Development: is There an Epigenetic Link?","authors":"Giovane G Tortelote","doi":"10.1007/s11892-024-01569-9","DOIUrl":"10.1007/s11892-024-01569-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review explores the mechanisms through which gestational diabetes mellitus GDM impacts fetal kidney development, focusing on epigenetic alterations as mediators of these effects. We examine the influence of GDM on nephrogenesis and kidney maturation, exploring how hyperglycemia-induced intrauterine stress can reduce nephron endowment and compromise renal function via dysregulation of normal epigenetic mechanisms.</p><p><strong>Recent findings: </strong>In addition to metabolic impacts, emerging evidence suggests that GDM exerts its influence through epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA expression, which disrupt gene expression patterns critical for kidney development. Recently, specific epigenetic modifications observed in offspring exposed to GDM were implicated in aberrant activation or repression of genes essential for kidney development. Key pathways influenced by these epigenetic changes, such as oxidative stress response, inflammatory regulation, and metabolic pathways, are discussed to illustrate the broad molecular impact of GDM on renal development. Finally, we consider potential intervention strategies that could mitigate the adverse effects of GDM on kidney development. These include optimizing maternal glycemic control, dietary modifications, dietary supplementation, and pharmacological agents targeting epigenetic pathways. Through a comprehensive synthesis of current research, this review underscores the importance of early preventive strategies to reduce the burden of kidney disease in individuals exposed to GDM and highlights key epigenetic mechanisms altered during GDM that impact kidney development.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"13"},"PeriodicalIF":5.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16DOI: 10.1007/s11892-024-01566-y
Vasco Costa, Bárbara Pereira, Susana R Patton, Tânia Brandão
Purpose of review: This review aimed to summarize the evidence regarding the relationship between parental psychosocial (e.g., fear of hypoglycemia, stress and family conflict) and glycemic outcomes in children between the age of 1-10 years old.
Recent findings: Type 1 Diabetes (T1D) in young children can be very complex to manage for their parents since they are the main individuals responsible for T1D tasks. Also, parental psychological adjustment impacts children's glycemic outcomes. This systematic review was performed following the PRISMA guidelines. The search process was conducted in four databases from 2019 to 2024. From a total of 215 studies, 5 were included. We identified five studies that found direct associations between parental psychosocial variables and children's glycemic outcomes. These findings suggest a unidirectional perspective, evidencing the need to examine the longitudinal interplay between these variables. In sum, promoting parental psychological interventions may be fundamental for enhancing children's glycemic outcomes.
{"title":"Parental Psychosocial Variables and Glycemic Control in T1D Pediatric Age: A Systematic Review.","authors":"Vasco Costa, Bárbara Pereira, Susana R Patton, Tânia Brandão","doi":"10.1007/s11892-024-01566-y","DOIUrl":"10.1007/s11892-024-01566-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aimed to summarize the evidence regarding the relationship between parental psychosocial (e.g., fear of hypoglycemia, stress and family conflict) and glycemic outcomes in children between the age of 1-10 years old.</p><p><strong>Recent findings: </strong>Type 1 Diabetes (T1D) in young children can be very complex to manage for their parents since they are the main individuals responsible for T1D tasks. Also, parental psychological adjustment impacts children's glycemic outcomes. This systematic review was performed following the PRISMA guidelines. The search process was conducted in four databases from 2019 to 2024. From a total of 215 studies, 5 were included. We identified five studies that found direct associations between parental psychosocial variables and children's glycemic outcomes. These findings suggest a unidirectional perspective, evidencing the need to examine the longitudinal interplay between these variables. In sum, promoting parental psychological interventions may be fundamental for enhancing children's glycemic outcomes.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"11"},"PeriodicalIF":5.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16DOI: 10.1007/s11892-024-01570-2
Alana M Ewen
Purpose of review: This literature review highlights the behavioral and biological mechanisms that link racial discrimination to type 2 diabetes (T2D) risk, self-management, and related complications in the Black population in the United States. Next steps are discussed and include recommendations for disease mitigation.
Recent findings: Black Americans are exposed to high levels of stress, with many stressors rooted in racial discrimination, a psychosocial factor that inhibits positive behavior change and disrupts bodily systems and functioning. T2D is a largely preventable disease, yet Black Americans experience known structural and systemic barriers (i.e., structural racism) that profoundly impact diabetes onset and progression. While causal mechanisms that link racial discrimination and T2D have become a more recent focus of study, a dearth of research on racial discrimination-related stress, and the role it plays in the onset and self-management of T2D, remains. Identifying the structural and contextual factors, specifically racial discrimination, that influence diabetes risk and self-management among Black adults is important in closing the gap in health disparities. Findings on coping strategies adopted across the African diaspora are also warranted as policy makers, researchers, and clinicians work together to create an actionable path forward.
{"title":"The Influence of Racial Discrimination as a Chronic Stressor on Type 2 Diabetes Risk and Self-Management Behaviors among Black Adults: A Scoping Review.","authors":"Alana M Ewen","doi":"10.1007/s11892-024-01570-2","DOIUrl":"10.1007/s11892-024-01570-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>This literature review highlights the behavioral and biological mechanisms that link racial discrimination to type 2 diabetes (T2D) risk, self-management, and related complications in the Black population in the United States. Next steps are discussed and include recommendations for disease mitigation.</p><p><strong>Recent findings: </strong>Black Americans are exposed to high levels of stress, with many stressors rooted in racial discrimination, a psychosocial factor that inhibits positive behavior change and disrupts bodily systems and functioning. T2D is a largely preventable disease, yet Black Americans experience known structural and systemic barriers (i.e., structural racism) that profoundly impact diabetes onset and progression. While causal mechanisms that link racial discrimination and T2D have become a more recent focus of study, a dearth of research on racial discrimination-related stress, and the role it plays in the onset and self-management of T2D, remains. Identifying the structural and contextual factors, specifically racial discrimination, that influence diabetes risk and self-management among Black adults is important in closing the gap in health disparities. Findings on coping strategies adopted across the African diaspora are also warranted as policy makers, researchers, and clinicians work together to create an actionable path forward.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"12"},"PeriodicalIF":5.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-09DOI: 10.1007/s11892-024-01564-0
Anja Cannon, Caitlon Jacoby, Allyson S Hughes
Purpose of review: The co-occurrence of diabetes and mental illnesses such as bipolar disorder (BD), obsessive-compulsive disorder (OCD), and schizophrenia creates significant barriers for both people with diabetes (PWD) and their healthcare teams. This literature review provides an analysis of the relationship between diabetes and mental illnesses through exploring epidemiology, shared risk factors, and clinical implications. The aim is to enhance the understanding of these complex comorbidities to guide and improve future research and clinical practice.
Recent findings: Recent research suggests a strong link between mental illness, metabolic syndrome, and diabetes. Studies show that BD has a robust relationship with metabolic disease and the antipsychotic medications used in treatment for many mental illnesses are strongly associated with weight gain and metabolic disease. However, there is limited research exploring the bidirectional relationship that diabetes has with BD, schizophrenia, and OCD. While research exists on the link between diabetes and mental conditions such as depression and anxiety, little research has examined schizophrenia, OCD and BD. The findings noted in this review suggest gaps in treatment options, healthcare services, and social support. While this paper provides a foundation for future progress, advancement in this field will require a collaborative effort from researchers, healthcare professionals, and community outreach programs to effectively close the gaps in care noted in these patient populations.
{"title":"Mind in Metabolism - A Comprehensive Literature Review on Diabetes and its Connections to Obsessive Compulsive Disorder, Schizophrenia, and Bipolar Disorder.","authors":"Anja Cannon, Caitlon Jacoby, Allyson S Hughes","doi":"10.1007/s11892-024-01564-0","DOIUrl":"10.1007/s11892-024-01564-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>The co-occurrence of diabetes and mental illnesses such as bipolar disorder (BD), obsessive-compulsive disorder (OCD), and schizophrenia creates significant barriers for both people with diabetes (PWD) and their healthcare teams. This literature review provides an analysis of the relationship between diabetes and mental illnesses through exploring epidemiology, shared risk factors, and clinical implications. The aim is to enhance the understanding of these complex comorbidities to guide and improve future research and clinical practice.</p><p><strong>Recent findings: </strong>Recent research suggests a strong link between mental illness, metabolic syndrome, and diabetes. Studies show that BD has a robust relationship with metabolic disease and the antipsychotic medications used in treatment for many mental illnesses are strongly associated with weight gain and metabolic disease. However, there is limited research exploring the bidirectional relationship that diabetes has with BD, schizophrenia, and OCD. While research exists on the link between diabetes and mental conditions such as depression and anxiety, little research has examined schizophrenia, OCD and BD. The findings noted in this review suggest gaps in treatment options, healthcare services, and social support. While this paper provides a foundation for future progress, advancement in this field will require a collaborative effort from researchers, healthcare professionals, and community outreach programs to effectively close the gaps in care noted in these patient populations.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"10"},"PeriodicalIF":5.2,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-04DOI: 10.1007/s11892-024-01568-w
Taynara Formagini, Christopher J Gonzalez, Julie Dias, Elva M Arredondo, Eric Hekler, Matthew J O'Brien
Purpose of review: Text-messaging interventions effectively prevent and manage numerous health conditions. This scoping review evaluates recent literature on text-messaging interventions focused on diabetes prevention, highlighting their development, associated outcomes, reach, and potential sustainability.
Recent findings: A total of 28 studies met eligibility criteria and were included in this review. Text-messaging was often used as a primary intervention method, focusing on promoting weight loss through physical activity and dietary changes. Studies also explored hybrid approaches integrating text-messaging with in-person sessions or other digital platforms. Intervention development involved multi-phase content creation, often leveraging established diabetes prevention curricula. Studies generally reported high feasibility and acceptability, although effectiveness was mixed. Cost-effectiveness comparisons favored text-messaging over traditional in-person programs. Implementation strategies aligned interventions with existing healthcare workflows, facilitating scalability and integration into routine care practices. Text-messaging interventions demonstrate considerable promise but require further refinement to ensure their effectiveness, particularly in enhancing participant engagement to ensure effectiveness and sustainability. Future research should focus on refining intervention content, integrating interactive features, and expanding cost-effectiveness evaluations to support broader implementation in real-world settings.
{"title":"Advancing Type 2 Diabetes Prevention through Text-Messaging Interventions: A Narrative Review.","authors":"Taynara Formagini, Christopher J Gonzalez, Julie Dias, Elva M Arredondo, Eric Hekler, Matthew J O'Brien","doi":"10.1007/s11892-024-01568-w","DOIUrl":"10.1007/s11892-024-01568-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Text-messaging interventions effectively prevent and manage numerous health conditions. This scoping review evaluates recent literature on text-messaging interventions focused on diabetes prevention, highlighting their development, associated outcomes, reach, and potential sustainability.</p><p><strong>Recent findings: </strong>A total of 28 studies met eligibility criteria and were included in this review. Text-messaging was often used as a primary intervention method, focusing on promoting weight loss through physical activity and dietary changes. Studies also explored hybrid approaches integrating text-messaging with in-person sessions or other digital platforms. Intervention development involved multi-phase content creation, often leveraging established diabetes prevention curricula. Studies generally reported high feasibility and acceptability, although effectiveness was mixed. Cost-effectiveness comparisons favored text-messaging over traditional in-person programs. Implementation strategies aligned interventions with existing healthcare workflows, facilitating scalability and integration into routine care practices. Text-messaging interventions demonstrate considerable promise but require further refinement to ensure their effectiveness, particularly in enhancing participant engagement to ensure effectiveness and sustainability. Future research should focus on refining intervention content, integrating interactive features, and expanding cost-effectiveness evaluations to support broader implementation in real-world settings.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"9"},"PeriodicalIF":5.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-02DOI: 10.1007/s11892-024-01556-0
Lily Nguyen, Skandan Shanmugan
Purpose of review: This article aims to review the recent literature assessing the relationship between obesity and colorectal carcinogenesis, the effect of obesity on the treatment of colorectal cancer (CRC), tools available to help augment the increased risk, and outcomes for patients who are affected by both obesity and colorectal cancer.
Recent findings: The biochemical mechanisms contributing to CRC carcinogenesis are not well understood but are suspected to be related to adipose tissue leading to a pro-inflammatory state and changes in the gut microbiome. Individuals with obesity are at higher risk for CRC development, worse oncologic outcomes, and increased rates of post-operative complications. Bariatric surgery decreases CRC risk but results with GLP-1 agonists are heterogeneous. Prehabilitation is the only weight loss method that has been demonstrated to decrease risks of post-operative morbidity in this population. Obesity augments CRC risk and outcomes. There are persistent knowledge gaps in etiology and epidemiology for the increased CRC risk in obese patients and more research is required to identify the therapeutic advantage of weight loss on CRC risk.
{"title":"A Review Article: The Relationship Between Obesity and Colorectal Cancer.","authors":"Lily Nguyen, Skandan Shanmugan","doi":"10.1007/s11892-024-01556-0","DOIUrl":"10.1007/s11892-024-01556-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>This article aims to review the recent literature assessing the relationship between obesity and colorectal carcinogenesis, the effect of obesity on the treatment of colorectal cancer (CRC), tools available to help augment the increased risk, and outcomes for patients who are affected by both obesity and colorectal cancer.</p><p><strong>Recent findings: </strong>The biochemical mechanisms contributing to CRC carcinogenesis are not well understood but are suspected to be related to adipose tissue leading to a pro-inflammatory state and changes in the gut microbiome. Individuals with obesity are at higher risk for CRC development, worse oncologic outcomes, and increased rates of post-operative complications. Bariatric surgery decreases CRC risk but results with GLP-1 agonists are heterogeneous. Prehabilitation is the only weight loss method that has been demonstrated to decrease risks of post-operative morbidity in this population. Obesity augments CRC risk and outcomes. There are persistent knowledge gaps in etiology and epidemiology for the increased CRC risk in obese patients and more research is required to identify the therapeutic advantage of weight loss on CRC risk.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"8"},"PeriodicalIF":5.2,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-09-26DOI: 10.1007/s11892-024-01554-2
Tasiyah Essop, Kyle Tran, Amanda C Purdy, Shaun C Daly
Purpose of review: The purpose of this review is to assess the effects of glucagon-like peptide-1 (GLP-1) agonists, sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus (T2DM) remission. This review explores the efficacy, safety, and durability of these surgical and medical modalities of diabetes management.
Recent findings: Studies have shown that GLP-1 agonists achieve higher rates of T2DM remission compared to standard glucose-lowering medications and lifestyle changes. In addition to weight loss, bariatric surgery has been found to be highly effective in treating and inducing remission of T2DM. Studies suggest that post-surgical patients see enhanced glycemic control. Both surgical interventions and GLP1 agonists are effective in achieving T2DM remission. Long-term follow-up and randomized controlled trials comparing bariatric surgery and GLP-1 agonists are necessary to evaluate their relative effectiveness in T2DM control. Further research is also needed to assess the combined effects of these treatment modalities.
{"title":"Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes.","authors":"Tasiyah Essop, Kyle Tran, Amanda C Purdy, Shaun C Daly","doi":"10.1007/s11892-024-01554-2","DOIUrl":"10.1007/s11892-024-01554-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to assess the effects of glucagon-like peptide-1 (GLP-1) agonists, sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus (T2DM) remission. This review explores the efficacy, safety, and durability of these surgical and medical modalities of diabetes management.</p><p><strong>Recent findings: </strong>Studies have shown that GLP-1 agonists achieve higher rates of T2DM remission compared to standard glucose-lowering medications and lifestyle changes. In addition to weight loss, bariatric surgery has been found to be highly effective in treating and inducing remission of T2DM. Studies suggest that post-surgical patients see enhanced glycemic control. Both surgical interventions and GLP1 agonists are effective in achieving T2DM remission. Long-term follow-up and randomized controlled trials comparing bariatric surgery and GLP-1 agonists are necessary to evaluate their relative effectiveness in T2DM control. Further research is also needed to assess the combined effects of these treatment modalities.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"273-289"},"PeriodicalIF":5.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}